Cargando…
Incidence and relative risk of peripheral neuropathy in cancer patients treated with eribulin: a meta-analysis
BACKGROUND: Eribulin is a microtubule inhibitor, which is approved for the treatment of breast cancer. Peripheral neuropathy has been reported in the studies of eribulin, but the incidence and relative risk (RR) of eribulin-associated peripheral neuropathy varied greatly in cancer patients. The purp...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Impact Journals LLC
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762380/ https://www.ncbi.nlm.nih.gov/pubmed/29340112 http://dx.doi.org/10.18632/oncotarget.21057 |